|
- One shot to stop HIV: MITs bold vaccine breakthrough
Massachusetts Institute of Technology "One shot to stop HIV: MIT's bold vaccine breakthrough " ScienceDaily ScienceDaily, 20 June 2025 <www sciencedaily com releases 2025 06
- Supercharged vaccine could offer strong protection with just . . .
Researchers generated a strong immune response to HIV with just one vaccine dose, by adding two powerful adjuvants to the vaccine This strategy could lead to vaccines that only need to be given once, for infectious diseases including HIV or SARS-CoV-2
- Step by Step Scientists Move Closer to an HIV Vaccine . . .
And that is how science wins—not in a single breakthrough, but in a sequence of precisely placed steps that bring humanity closer to solving one of the most complex puzzles of our time Reference: Jordan R Willis et al, Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans, Science (2025)
- HIV Breakthrough: Just two jabs in one year, near zero HIV . . .
Scientists have created a powerful new weapon against HIV: a simple injection that protects you for six months with just two shots a year Called Yeztugo (Lenacapavir), this breakthrough drug is 99 9 per cent effective at stopping HIV infection, according to major trials in Africa
- Always ‘one atom away’: The long, rocky journey to an HIV . . .
Note: Lenacapavir PrEP was Science’s 2024 Breakthrough of the Year For his contribution to its development, Sundquist was awarded the AAAS Mani L Bhaumik Breakthrough of the Year Award on 8 May, along with Moupali Das,vice president, clinical development, HIV prevention and pediatrics at Gilead; and Yvette Raphael, co-founder and executive director of Advocacy for Prevention of HIV and AIDS
- One Shot To Stop HIV: MITs Bold Vaccine Breakthrough
ScienceDaily reports: Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one dose By combining two immune-boosting adjuvants alum and SMNP the vaccine lingers in lymph nodes for nearly a month, encouraging the body to produce a vast array of antibodies
- Two-part vaccine strategy generates a stronger, longer . . .
LA JOLLA, CA—In the quest to develop an effective HIV vaccine, scientists from Scripps Research have made a significant leap forward They found that a two-part delivery strategy can train the immune system to produce a stronger response to HIV, offering new hope in the fight against one of the world’s most elusive viruses
|
|
|